<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1112</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15814718</PubmedId>
            <Abstract>The spike (S) protein of severe acute respiratory syndrome associated coronavirus (SARS-CoV) is a major antigenic determinant capable of inducing protective immunity. Recently, a small fragment on the SARS-CoV S protein (residues 318-510) was characterized as a minimal receptor-binding domain (RBD), which mediates virus binding to angiotensin-converting enzyme 2, the functional receptor on susceptible cells. In this study, we demonstrated that a fusion protein containing RBD linked to human IgG1 Fc fragment (designated RBD-Fc) induced high titer of RBD-specific Abs in the immunized mice. The mouse antisera effectively neutralized infection by both SARS-CoV and SARS pseudovirus with mean 50% neutralization titers of 1/15,360 and 1/24,737, respectively. The neutralization determinants on the RBD of S protein were characterized by a panel of 27 mAbs isolated from the immunized mice. Six groups of conformation-dependent epitopes, designated as Conf I-VI, and two adjacent linear epitopes were identified by ELISA and binding competition assays. The Conf IV and Conf V mAbs significantly blocked RBD-Fc binding to angiotensin-converting enzyme 2, suggesting that their epitopes overlap with the receptor-binding sites in the S protein. Most of the mAbs (23 of 25) that recognized the conformational epitopes possessed potent neutralizing activities against SARS pseudovirus with 50% neutralizing dose ranging from 0.005 to 6.569 microg/ml. Therefore, the RBD of SARS S protein contains multiple conformational epitopes capable of inducing potent neutralizing Ab responses, and is an important target site for developing vaccines and immunotherapeutics.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>4908-15</ArticlePages>
            <ArticleTitle>Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>He</LastName>
                    <ForeName>Yuxian</ForeName>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Hong</ForeName>
                </Author>
                <Author>
                    <LastName>Siddiqui</LastName>
                    <ForeName>Pamela</ForeName>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Yusen</ForeName>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Shibo</ForeName>
                </Author>
            </Authors>
            <Affiliations>Viral Immunology Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antibodies, Viral;Antigens, Viral;Epitopes;MHV surface projection glycoprotein;Membrane Glycoproteins;Peptide Fragments;Receptors, Virus;Recombinant Fusion Proteins;Spike Glycoprotein, Coronavirus;Viral Envelope Proteins;spike glycoprotein, SARS-CoV</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antibodies, Viral(biosynthesis); Antigens, Viral(chemistry; genetics); Binding Sites; Cell Line; Chlorocebus aethiops; Epitopes(chemistry; genetics); Humans; In Vitro Techniques; Membrane Glycoproteins(chemistry; genetics; immunology; metabolism); Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neutralization Tests; Peptide Fragments(chemistry; genetics; immunology); Protein Conformation; Receptors, Virus(metabolism); Recombinant Fusion Proteins(chemistry; genetics; immunology); SARS Virus(genetics; immunology; pathogenicity); Spike Glycoprotein, Coronavirus; Vero Cells; Viral Envelope Proteins(chemistry; genetics; immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>174</Volume>
                <Issue>8</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>p435-451</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NYNYKYRYLRHGKLRPF</LinearSequence>
                        <StartingPosition>435</StartingPosition>
                        <EndingPosition>451</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P59594.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>694009</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 4911</LocationOfData>
                <EpitopeId>46681</EpitopeId>
                <ReferenceStartingPosition>435</ReferenceStartingPosition>
                <ReferenceEndingPosition>451</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>17-mer shown to be recognized by one out of 27 mAbs raised against receptor binding domain (RBD) of source protein. Also known as Peplomer protein and E2.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <BCellId>15387</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>4 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVLYNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATV</LinearSequence>
                                            <StartingPosition>313</StartingPosition>
                                            <EndingPosition>510</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P59594.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Receptor binding domain (aa313-510)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 immunizations 3 wks apart, first with 20 micrograms, following with 10 micrograms.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>mAbs hybridomas were generated from immune splenocytes by fusion with SP2/0 myeloma cell line. The carrier was composed of Fc domain.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>1 out of 27 anti-RBD (receptor binding domain of source protein) mAbs assayed recognize this linear peptide. One other mAb also recognizes an adjacent linear epitope, while 25 recognize conformational epitopes.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>4D5</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>p435-451</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NYNYKYRYLRHGKLRPF</LinearSequence>
                                        <StartingPosition>435</StartingPosition>
                                        <EndingPosition>451</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table I</LocationOfData>
                        <BCellId>15389</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>4 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVLYNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATV</LinearSequence>
                                            <StartingPosition>313</StartingPosition>
                                            <EndingPosition>510</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P59594.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Receptor binding domain (aa313-510)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 immunizations 3 wks apart, first with 20 micrograms, following with 10 micrograms.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>mAbs hybridomas were generated from immune splenocytes by fusion with SP2/0 myeloma cell line. The carrier was composed of Fc domain.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>mAb recognizing this linear peptide also recognize the source protein both in native and DTT treated forms. Other mAbs recognizing confromational epitopes do not react with the reduced form.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>4D5</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Spike glycoprotein precursor</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4 and table III</LocationOfData>
                        <BCellId>15390</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>4 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVLYNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATV</LinearSequence>
                                            <StartingPosition>313</StartingPosition>
                                            <EndingPosition>510</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P59594.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Receptor binding domain (aa313-510)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 immunizations 3 wks apart, first with 20 micrograms, following with 10 micrograms.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>mAbs hybridomas were generated from immune splenocytes by fusion with SP2/0 myeloma cell line. The carrier was composed of Fc domain.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>mAb recognizing this linear peptide is not able to compete binding of source protein RBD to its entry receptor (ACE2 enzyme) either in soluble or cell-associated forms.  SARS coronavirus infection of susceptible cells is not inhibited by this mAbs. Other mAbs recognizing conformational epitopes on RBD are able to effectively neutralize infection and inhibit receptor binding.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>4D5</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Spike glycoprotein precursor</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>p449-458</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RPFERDISNV</LinearSequence>
                        <StartingPosition>449</StartingPosition>
                        <EndingPosition>458</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P59594.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>694009</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 4911</LocationOfData>
                <EpitopeId>55148</EpitopeId>
                <ReferenceStartingPosition>449</ReferenceStartingPosition>
                <ReferenceEndingPosition>458</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Also known as Peplomer protein and E2.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4 and table III</LocationOfData>
                        <BCellId>15393</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>4 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVLYNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATV</LinearSequence>
                                            <StartingPosition>313</StartingPosition>
                                            <EndingPosition>510</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P59594.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Receptor binding domain (aa313-510)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 immunizations 3 wks apart, first with 20 micrograms, following with 10 micrograms.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>mAbs hybridomas were generated from immune splenocytes by fusion with SP2/0 myeloma cell line. The carrier was composed of Fc domain.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>mAb recognizing this linear epitope is not able to compete binding of source protein RBD to its entry receptor (ACE2 enzyme) either in soluble of cell-associated forms.  SARS coronavirus infection of susceptible cells is not inhibited by this mAbs. Other mAbs recognizing conformational epitopes on RBD are able to effectively neutralize infection and inhibit receptor binding.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>17H9</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Spike glycoprotein precursor</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <BCellId>15391</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>4 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVLYNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATV</LinearSequence>
                                            <StartingPosition>313</StartingPosition>
                                            <EndingPosition>510</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P59594.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Receptor binding domain (aa313-510)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 immunizations 3 wks apart, first with 20 micrograms, following with 10 micrograms.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>mAbs hybridomas were generated from immune splenocytes by fusion with SP2/0 myeloma cell line. The carrier was composed of Fc domain.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>1 out of 27 anti-RBD (receptor binding domain of source protein) mAbs assayed recognize this linear epitope, deduced by its binding to 2 adjacent 17-mers. One other mAb also recognizes an adjacent linear peptide, while 25 recognize conformational epitopes.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>17H9</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Spike glycoprotein 442-458</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YLRHGKLRPFERDISNV</LinearSequence>
                                        <StartingPosition>442</StartingPosition>
                                        <EndingPosition>458</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table I</LocationOfData>
                        <BCellId>15392</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>4 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVLYNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATV</LinearSequence>
                                            <StartingPosition>313</StartingPosition>
                                            <EndingPosition>510</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P59594.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Receptor binding domain (aa313-510)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>4 immunizations 3 wks apart, first with 20 micrograms, following with 10 micrograms.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>mAbs hybridomas were generated from immune splenocytes by fusion with SP2/0 myeloma cell line. The carrier was composed of Fc domain.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>mAb recognizing this linear epitope also recognize source protein both in native and DTT treated forms. Other mAbs recognizing confromational epitopes do not react with the reduced form.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>17H9</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Spike glycoprotein precursor</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

